Publicaciones en colaboración con investigadores/as de South London and Maudsley NHS Foundation Trust (21)

2024

  1. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  2. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003

2023

  1. Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants

    Schizophrenia bulletin, Vol. 49, Núm. 3, pp. 614-625

  2. Consensus Clinical Guidance for Diagnosis and Management of Adult COVID-19 Encephalopathy Patients

    Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 35, Núm. 1, pp. 12-27

  3. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  4. Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scale

    Schizophrenia, Vol. 9, Núm. 1

2022

  1. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475

  2. The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis

    Schizophrenia Bulletin Open, Vol. 3, Núm. 1

2021

  1. Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)

    Translational Psychiatry

  3. Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study

    Molecular Psychiatry, Vol. 26, Núm. 9, pp. 5307-5319

  4. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis

    Human Brain Mapping, Vol. 42, Núm. 2, pp. 439-451

  5. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes

    Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474

2020

  1. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

    Translational Psychiatry, Vol. 10, Núm. 1

  2. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study

    Neuropsychopharmacology, Vol. 45, Núm. 4, pp. 641-648

2018

  1. Cognitive remediation therapy for psychotic major depressive disorder

    Primary Care Companion to the Journal of Clinical Psychiatry

  2. The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): Protocol for a randomised controlled trial

    Trials, Vol. 19, Núm. 1

2016

  1. Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification

    JAMA Psychiatry, Vol. 73, Núm. 2, pp. 113-120

  2. Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity

    Human Brain Mapping, Vol. 37, Núm. 1, pp. 351-365

  3. Neurobiological models of self-disorders in early schizophrenia

    Schizophrenia Bulletin, Vol. 42, Núm. 4, pp. 874-880